Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Recruiting

Phase 2

CRN04894Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Sponsor:

Crinetics Pharmaceuticals Inc.

Code:

NCT05907291

Conditions

Congenital Adrenal Hyperplasia

Classic Congenital Adrenal Hyperplasia

Eligibility Criteria

Sex: All

Age: 16 - 70+

Healthy Volunteers: Not accepted

Interventions

CRN04894

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by Crinetics Pharmaceuticals Inc. on 2024-11-26.